Researchers published a pan-cancer patient-derived organoid (PDO) platform spanning 220 organoids from 191 patients across 15 cancer types, reporting high fidelity to parent tumors and reproducible long-term growth. The work, published in Science Advances, described conserved tumor heterogeneity, genomic concordance for driver mutations, and stable expression profiles over repeated passages. The team reported quantitative agreement metrics including 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a median 0.85 gene-expression correlation across passages. Clonality analysis indicated most dominant clones were preserved, supporting organoids as preclinical models. In functional testing, a subset of organoids representing tumors considered ineligible for PARP inhibitors still showed sensitivity in vitro: 58% responded to talazoparib. The findings point to potential use in uncovering therapeutic vulnerabilities beyond current clinical eligibility rules.